Brady Corp ($BRC) Just Bought Its Way Into Pole Position — And Nobody's Talking About It

Everyone's glued to oil prices and Fed confirmation theater right now — which is exactly when you should be hunting in the corners nobody's looking. Three tickers worth your attention this week.

$BRC (Brady Corporation) just dropped $1.4 billion — its largest acquisition ever — to scoop up Honeywell's industrial barcode and logistics scanning business. A ~$3.9B market cap company effectively cornering a niche that every warehouse, hospital, and factory on earth depends on. Bloomberg Intelligence flagged it, almost nobody else did. The deal potentially re-rates Brady from sleepy industrial to logistics-tech infrastructure play. Watch for integration updates in Q3.

Next up: $CMPS (Compass Pathways). The psilocybin biotech just surged 39% after Trump signed an executive order easing FDA restrictions — Bloomberg caught it buried under the Alphabet headlines. A rare-disease and mental health tailwind from a deregulation-friendly White House is exactly the kind of asymmetric catalyst that moves small-cap biotechs violently. And finally, for the contrarian with patience: private credit BDCs are eating traditional banks' lunch. Blue Owl's publicly traded vehicles are leveraged at less than 1x — laughably conservative compared to the 30-40x leverage banks ran pre-GFC — yet Jamie Dimon keeps screaming 'crisis.' The Seeking Alpha crowd is right to push back on that narrative.

Three companies, zero mainstream coverage, one very interesting setup — pick your poison.